![Leila Jaafar-Thiel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Leila Jaafar-Thiel
Directeur Général chez Swiss Nuclides AG
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Matthias Staehelin | M | - |
Nuclidium AG
![]() Nuclidium AG Miscellaneous Commercial ServicesCommercial Services Nuclidium AG is a private company located in Switzerland that is revolutionizing precision oncology by developing copper-based radiopharmaceuticals for targeted cancer treatment and diagnosis. The Swiss company's product portfolio utilizes the unique properties of copper to achieve improved safety and efficacy with advantageous economics for hospitals and patients. The company overcomes supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. Nuclidium's diverse and interdisciplinary team is focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients. The company's flexible CutraCeTM platform combines copper radiometals with highly specific cancer-targeting molecules to rapidly develop novel diagnostic and therapeutic programs. Nuclidium's differentiated "diagnostic to therapeutic" approach de-risks their development pathway. | - |
Gustav von Schulthess | M | - |
Nuclidium AG
![]() Nuclidium AG Miscellaneous Commercial ServicesCommercial Services Nuclidium AG is a private company located in Switzerland that is revolutionizing precision oncology by developing copper-based radiopharmaceuticals for targeted cancer treatment and diagnosis. The Swiss company's product portfolio utilizes the unique properties of copper to achieve improved safety and efficacy with advantageous economics for hospitals and patients. The company overcomes supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. Nuclidium's diverse and interdisciplinary team is focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients. The company's flexible CutraCeTM platform combines copper radiometals with highly specific cancer-targeting molecules to rapidly develop novel diagnostic and therapeutic programs. Nuclidium's differentiated "diagnostic to therapeutic" approach de-risks their development pathway. | 7 ans |
Erik Strömqvist | M | 54 |
Swiss Nuclides AG
![]() Swiss Nuclides AG Hospital/Nursing ManagementHealth Services Swiss Nuclides AG provides diagnostics and radiopharmaceutical therapy treatment services for cancer patients. The company is based in Aarau, Switzerland. The Swiss company was founded by Leila Jaafar-Thiel and Gustav von Schulthess, and Leila Jaafar-Thiel has been the CEO since incorporation. | - |
Anthony Wild | M | - |
Swiss Nuclides AG
![]() Swiss Nuclides AG Hospital/Nursing ManagementHealth Services Swiss Nuclides AG provides diagnostics and radiopharmaceutical therapy treatment services for cancer patients. The company is based in Aarau, Switzerland. The Swiss company was founded by Leila Jaafar-Thiel and Gustav von Schulthess, and Leila Jaafar-Thiel has been the CEO since incorporation. | - |
Mathias Staehelin | M | - |
Swiss Nuclides AG
![]() Swiss Nuclides AG Hospital/Nursing ManagementHealth Services Swiss Nuclides AG provides diagnostics and radiopharmaceutical therapy treatment services for cancer patients. The company is based in Aarau, Switzerland. The Swiss company was founded by Leila Jaafar-Thiel and Gustav von Schulthess, and Leila Jaafar-Thiel has been the CEO since incorporation. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Suisse | 5 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Leila Jaafar-Thiel
- Réseau Personnel